Human Biospecimens Market Revenue to Attain USD 24.53 Bn by 2033

11 Jul 2025

Share :

Table of Content

1. Human Biospecimens Market Revenue and Trends 2025 to 2033 2. Market Overview 3. Segment Insights 4. Regional Insights 5. Human Biospecimens Market Coverage 6. Human Biospecimens Market Key Players

Human Biospecimens Market Revenue and Trends 2025 to 2033

The global human biospecimens market revenue accounted for USD 13.4 billion in 2025 and is predicted to attain around USD 24.53 billion by 2033, growing at a CAGR of 7.85%. The rising cancer research activities is boosting the demand for high-quality human biospecimens, which is driving the growth of the human biospecimens market.

Market Overview

The global human biospecimens market is transforming due to various factors, including the growing requirement for early disease diagnosis and drug discovery. The increased prevalence of chronic and rare diseases has increased the need for novel clinical trials and the development of innovative therapies. Additionally, the rising demand for personalized medicines is driving the need for comprehensive biospecimens to facilitate early disease diagnosis and the development of new drugs and treatment solutions.

The demand for high-quality biospecimens in drug development has increased, creating numerous opportunities for innovative solutions in the emerging market. The biospecimen plays a vital role in R&D by providing a significant understanding of disease mechanisms and the development of novel drugs and treatments. The rising focus on advancing research and development is driving demand for high-quality biospecimens. Additionally, advancements in biobanking technologies further contribute to this demand.

Segment Insights

• By specimen type, the tissue specimens segment dominated the market in 2024 due to the existence of various biobanks for storing tissue specimens. The broad availability of tissue samples contributes to segment dominance. The widespread demand for tissue specimens in research, particularly cancer research, drives the segment.
• By application, the cancer research segment led the market in 2024 due to increased demand for biospecimens in cancer research. Biospecimens play a crucial role in cancer diagnosis and treatment. The growing need for advanced cancer therapies has increased the need for high-quality biospecimens.
• By end-user, the pharma & biotech companies segment held the largest market share in 2024 due to the large adoption of biospecimens by these companies for drug development, precision medicine, personalized treatments, and clinical trials. The increasing number of clinical trials and the need for research to detect potential drug targets and develop novel drugs and therapies drive demand for high-quality biospecimens among pharma and biotech companies.
• By storage type, the cold storage (-80°C or LN2) segment dominated the market in 2024, driven by its wide use in long-term preservation and maintenance of sample integrity. This storage type is crucial in applications such as cancer research, personalized medicine, and genomics.
• By procurement type, the retrospective (banked) samples segment led the market in 2024 due to their crucial role in biomedical research. The growing advancements in technologies and evolving research requirements are fostering the demand for retrospective (banked) samples. The increasing adoption of high-throughput technologies and analytical approaches has been observed in various research areas.

Regional Insights

North America dominated the human biospecimens market in 2024, driven by the region’s robust biobanking infrastructure and strong investments in R&D. Government support and funding for biomedical research are fueling the regional biobanking industry. The growing focus on the integration of cutting-edge technologies like AI in biobanking and the rising demand for precision medicine and personalized treatments are shaping the market growth.

Asia Pacific is expected to grow at the fastest rate during the forecast period due to the increased prevalence of chronic disease and focus on advancing biobanking. The rising demand for comprehensive biospecimens in personalized treatment options, diagnosis, and drug discovery is further contributing to the growth. The rising public-private collaborations and the expansion of the biobank industry in countries like China, Japan, and India support regional market growth.

Human Biospecimens Market Coverage

Recent Development

• In January 2025, a leading online marketplace for human biospecimens, iSpecimen Inc., secured its suppliers of the flu-like human metapneumovirus (hMPV). The virus has the potential to cause another COVID-style pandemic and has caused China’s hospitals to become overrun.

Human Biospecimens Market Key Players

• BioIVT
• Precision for Medicine
• BioChain Institute Inc.
• Conversant Bio (part of Discovery Life Sciences)
• Indivumed GmbH
• REPROCELL Inc.
• US Biolab Corporation, Inc.
• Biobank Graz (Medical University of Graz)
• ProteoGenex Inc.
• Seracare Life Sciences (part of LGC Group)
• Asterand Bioscience
• OriGene Technologies, Inc.
• Biomax Informatics AG
• Tissue Solutions Ltd.
• Human BioMolecular Research Institute (HBRI)
• AMS Bio (AMS Biotechnology)
• National Disease Research Interchange (NDRI)
• IQVIA (Biospecimen Services)
• Boca Biolistics
• BioRepository Inc.

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6378

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.co |+1 804 441 9344